The World Health Organisation (WHO), Geneva, has approved and included another of Ranbaxy Laboratories Limited’s anti retrovirals (ARV) drug in its pre-qualification list.

The product approved by WHO, Geneva, Abacavir 300 mg tablets, will be manufactured at Ranbaxy's WHO pre-qualified manufacturing site at Paonta Sahib, India. Abacavir is a nucleoside reverse transcriptase inhibitor and is widely used as part of first line anti retroviral treatment around the world.

With the inclusion of Abacavir 300 tablets, Ranbaxy now has 18 ARVs on the WHO pre-qualification list, including three US FDA approvals. Since 2001, Ranbaxy has been providing high quality ARV medicines, at affordable prices, to countries and patients afflicted by HIV/AIDS. The Company's ARVs have been used as mainstays in various large treatment programs, both National and NGO/Institutional. As a result, over 500,000 patients in more than 60 countries across Africa, Latin America, CIS and Asia, benefit from Ranbaxy ARV.